BioMarin Pharmaceuticals
BMRN
556 hedge funds and large institutions have $15.7B invested in BioMarin Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 103 funds opening new positions, 187 increasing their positions, 175 reducing their positions, and 48 closing their positions.
115% more first-time investments, than exits
New positions opened: 103 | Existing positions closed: 48
60% more funds holding in top 10
Funds holding in top 10: 5 → 8 (+3)
15% more capital invested
Capital invested by funds: $13.6B → $15.7B (+$2.03B)
12% more call options, than puts
Call options by funds: $160M | Put options by funds: $142M
8% more funds holding
Funds holding: 513 → 556 (+43)
7% more repeat investments, than reductions
Existing positions increased: 187 | Existing positions reduced: 175
0.35% more ownership
Funds ownership: 96.25% → 96.6% (+0.35%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$237M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$121M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$108M |
| 4 |
PA
Perceptive Advisors
New York
|
+$97.4M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$76.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$410M |
| 2 |
JP Morgan Chase
New York
|
-$135M |
| 3 |
BlackRock
New York
|
-$117M |
| 4 |
Goldman Sachs
New York
|
-$55.4M |
| 5 |
DLPIC
Davide Leone & Partners Investment Company
London,
United Kingdom
|
-$55.3M |
BMRN Hedge Fund Activity: Q4 2021 in Review
556 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2021, worth a combined $15.7B — up 15% from $13.6B a quarter earlier.
Buyers outnumbered sellers: 103 funds opened new BMRN positions and 48 closed out — a net gain of 55 holders — while 187 added to existing stakes and 175 trimmed.
The largest buyer was Viking Global Investors, opening a new position worth an estimated $237M. The largest seller was Capital Research Global Investors, cutting an estimated $410M.
- 556 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2021, up from 513 in Q3 2021.
- Funds reported $15.7B of BioMarin Pharmaceuticals stock for Q4 2021, up 15% quarter-over-quarter.
- 103 funds opened new BioMarin Pharmaceuticals positions in Q4 2021 and 48 closed out, a net change of +55 holders.
- The largest BioMarin Pharmaceuticals buyer in Q4 2021 was Viking Global Investors, an estimated $237M added.
- The largest BioMarin Pharmaceuticals seller in Q4 2021 was Capital Research Global Investors, an estimated $410M sold.
Based on aggregated 13F filings for Q4 2021.